<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-17_23-23-32</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>- If pathologic confirmation of progression is absent, then prioritize multidisciplinary review before escalating beyond current systemic therapy.  
- If comprehensive germline/somatic testing (including SMARCA4, BRCA, HRD, MSI, TMB, PD-L1) is pending/unknown, then obtain urgently before choosing next-line strategy.  
- If renal function or hydronephrosis worsens from tumor encasing ureter/renal vein, then shift focus from disease control to decompression and organ preservation.  
- If performance status declines or toxicities from multi-agent therapy accumulate, then de-escalate to less intensive systemic or purely supportive care.  
- If any actionable alteration or clinical trial option is identified, then transition from empiric multi-agent regimens to biomarker- or trial-directed therapy.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢癌术后化疗中：HER2（1+）2024.05.10宁波市妇女儿童医院盆腔MR：盆腔子宫前方可见一较大实性病灶，形态不规则，大小101*95*140mm，中心见多囊状，肿块紧贴子宫前壁，增强后肿块明显不均匀强化；右侧卵巢见显示，左侧卵巢显示不明确；盆腔内未见淋巴结增大，盆腔少量积液；盆腔占位，肉瘤可能。2024.05.22全麻下开腹全子宫双附件+大网膜+阑尾切除术+腹主动脉旁淋巴结清扫术+盆腔肿块切除术（女性）+肠粘连松解术+瘤体减灭术卵巢恶性肿瘤：（左附件及盆腔巨大肿块）小圆细胞恶性肿瘤，正在行免疫组化检查辅助诊断。补充诊断1：初步报告: （左附件及盆腔巨大肿块）小圆细胞恶性肿瘤，结合免疫组化结果，符合高钙血症型小细胞癌，大小16.5*13.5*8 cm。免疫组化结果（HI24-22759）：AE1/AE3（少+），CK（少+），CD20（-），CD3（-），CD99（+），SMARCA4 BRG1（-），SMARCA2(BRM)（-），SMARCB1(INI-1)（+），CD10（少+），Desmin（-），MyoD1（-），Myogenin（-），P53（少+），PAX8（-），Ki-67（+80%），WT1（+），ER（-），PR（-），Syn（少+），CgA（-），INSM1（-），LCA（-） ;（全子宫）内膜呈分泌改变；宫颈慢性炎。（右附件）未见特殊异常。（左卵巢血管）纤维血管组织。（阑尾）慢性炎。（腹主动脉旁）淋巴结（0/14）未见肿瘤转移。（左髂总）淋巴结（0/6）未见肿瘤转移。2024.06.27患者签署“奈妥匹坦/帕洛诺司琼复方联合奥氮平基础上减免地塞米松对于高致吐方案止吐效果的影响：一项III期非劣效性随机试验”的知情同意书（版本号：V1.1，版本日期：2024.02.29），中心：01，组别：组3，筛选号：01-047，随机号：114。2024.06.27-2024.08.09行C1-C3程EP方案治疗，具体：【依托泊苷0.16g d1-3+顺铂 40mg d1-3 ivgtt，q3w。C3开始加用贝伐珠单抗400mg d1。】8.13 盆腔MRI：卵巢癌术后改变，系膜、腹膜散在结节，考虑转移，请结合临床。2024.08.29起行C1程【贝伐珠单抗400mg+奥沙利铂200mg d1+白蛋白结合型紫杉醇400mg d1，q3w】 9.2 腹部CT：腹膜后新见多发肿大淋巴结，M可能，请结合临床。肝内多发血管瘤可能同前相仿，请结合MRI检查。腹腔少量积液。【依托泊甙+顺铂*3，第三次加用贝伐，第四次换成白紫+奥博+贝伐*3】，末次化疗10.11 10.11CA125:7.14U/ml,CYFRA21-1:2.26ng/ml,NSE:12.80ng/ml,PROGRP:60.20pg/mL,HE4:71.80pmol/L↑,ROMA:15.38%(绝经前)↑,ROMA.:9.92%(绝经后) 10.23外院MRI： 卵巢肿瘤术后改变，两侧腹股沟数个淋巴结。 MRI复片：卵巢肿瘤术后改变，两侧腹股沟小淋巴结。腹部检查未做，无法评估腹膜后淋巴结情况。于2024.9.20-2024.10.11起行C2-C3程减量化疗：【贝伐珠单抗400mg+奥沙利铂160mg d1+白蛋白结合型紫杉醇320mg d1，q3w，C3后外院加用AK-104治疗2程】一共四周期； 24.12.15 HE4 93 24.12.03 总钙：2.46后【BEV+AK104】4次。CT（2024.12.09）：腹膜后多发肿大淋巴结，部分较前略缩小；左输尿管上段受累可能，伴左肾积水；请结合临床。肝内多发血管瘤可能同前相仿，请结合MRI检查。腹腔少量积液。2025.2.1 后腹膜区多发转移瘤，部分累及左侧输尿管可能，肝脏中叶稍低密度灶，左肾包膜下征象，转移可能，腹腔盆腔、腹膜后、双腹股沟多发淋巴结显示25.1 HE4 300+25.2 HE4 224.8发热 持续10余天，布洛芬控制复片：腹膜后多发肿大淋巴结，较前增大；左输尿管上段及左肾受累可能，左肾周渗出；肝内多发血管瘤同前。双侧腹股沟多发稍大淋巴结。2025.02.06 德曲+奥铂+贝伐 3程，第3程未用奥铂2025.03.28 HE4 117 较前增高2025.03.28 AKP 218 PLT 632025.02.27 US示病灶10cm较前相仿2025.03.15 US：后腹膜低回声10.6cm，较前相仿2025.04.14 德曲+奥沙利铂+贝伐，HE4 3042025.05.14 德曲+帕博利珠单抗+奥沙利铂2025.05.06 CT：病灶4.6*4.2cm，HE4 2502025.06.07 德曲+帕博利珠单抗，HE4　267诉CA199上升，2025.06.06 56，下降趋势2025.06.06 CT增强：病灶7.3cm诉肿瘤增大，咨询药物CT复片：腹膜后肿块，较2025.5增大，累及左肾静脉、输尿管、腰大肌，包绕腹主动脉；肝左叶血管瘤。</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;Multiple cycles across regimens as documented (see timeline)&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;依托泊苷0.16g d1-3+顺铂 40mg d1-3 ivgtt，q3w（EP）&quot;,&quot;贝伐珠单抗400mg+奥沙利铂200mg d1+白蛋白结合型紫杉醇400mg d1，q3w&quot;,&quot;贝伐珠单抗400mg+奥沙利铂160mg d1+白蛋白结合型紫杉醇320mg d1，q3w&quot;,&quot;BEV+AK-104&quot;,&quot;德曲+奥铂+贝伐&quot;,&quot;德曲+帕博利珠单抗+奥沙利铂&quot;,&quot;德曲+帕博利珠单抗&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;7.14 U/ml (2024-10-11)&quot;,&quot;HE4&quot;:&quot;267 pmol/L (2025-06-07)&quot;,&quot;HER2&quot;:&quot;1+ (2024-05-10)&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Postoperative ovarian small cell carcinoma (hypercalcemic type); receiving systemic therapy with recent radiologic progression (2025-06-06).&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;小圆细胞恶性肿瘤&quot;],&quot;histology&quot;:&quot;高钙血症型小细胞癌&quot;,&quot;laterality&quot;:&quot;Left&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary/pelvis&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;C1-C3&quot;,&quot;end_date&quot;:&quot;2024-08-09&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;依托泊苷0.16g d1-3+顺铂 40mg d1-3 ivgtt，q3w（EP）；C3开始加用贝伐珠单抗400mg d1&quot;,&quot;start_date&quot;:&quot;2024-06-27&quot;},{&quot;cycles&quot;:&quot;Multiple (documented through 2024-10-11)&quot;,&quot;end_date&quot;:&quot;2024-10-11&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;2L&quot;,&quot;regimen&quot;:&quot;贝伐珠单抗400mg+奥沙利铂200mg d1+白蛋白结合型紫杉醇400mg d1，q3w (dose modifications later to 160mg/320mg)&quot;,&quot;start_date&quot;:&quot;2024-08-29&quot;},{&quot;cycles&quot;:&quot;4 (dates approximate as documented)&quot;,&quot;end_date&quot;:&quot;2024-12-15&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;3L&quot;,&quot;regimen&quot;:&quot;BEV+AK-104 (外院加用AK-104 2 cycles; BEV+AK104 x4 documented)&quot;,&quot;start_date&quot;:&quot;2024-12-03&quot;},{&quot;cycles&quot;:&quot;Multiple (documented through 2025-06-07)&quot;,&quot;end_date&quot;:&quot;2025-06-07&quot;,&quot;intent&quot;:&quot;Palliative&quot;,&quot;line&quot;:&quot;4L+&quot;,&quot;regimen&quot;:&quot;德曲+奥铂+贝伐 (2025.02.06 start; third cycle omitted oxaliplatin); later 德曲+奥沙利铂+贝伐; 德曲+帕博利珠单抗+奥沙利铂; 德曲+帕博利珠单抗&quot;,&quot;start_date&quot;:&quot;2025-02-06&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;No&quot;,&quot;PFI_days&quot;:&quot;23&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;4&quot;,&quot;end_date&quot;:&quot;2024-08-09&quot;,&quot;evidence&quot;:&quot;2024-08-13 pelvic MRI: mesenteric and peritoneal nodules, consider metastases&quot;,&quot;evidence_type&quot;:&quot;Radiologic&quot;,&quot;first_relapse_date&quot;:&quot;2024-08-13&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2024-06-27&quot;,&quot;status&quot;:&quot;Refractory&quot;},{&quot;PFI_days&quot;:&quot;113&quot;,&quot;end_date&quot;:&quot;2024-10-11&quot;,&quot;evidence&quot;:&quot;2025-02-01 CT/scan: multiple retroperitoneal metastatic lesions; left ureter/left kidney involvement possible&quot;,&quot;evidence_type&quot;:&quot;Radiologic&quot;,&quot;first_relapse_date&quot;:&quot;2025-02-01&quot;,&quot;line&quot;:&quot;2L&quot;,&quot;start_date&quot;:&quot;2024-08-29&quot;,&quot;status&quot;:&quot;Resistant&quot;},{&quot;PFI_days&quot;:&quot;23&quot;,&quot;end_date&quot;:&quot;2025-05-14&quot;,&quot;evidence&quot;:&quot;2025-06-06 CT enhanced: retroperitoneal mass increased vs 2025-05; lesion 7.3cm, involving left renal vein/ureter, encasing aorta&quot;,&quot;evidence_type&quot;:&quot;Radiologic&quot;,&quot;first_relapse_date&quot;:&quot;2025-06-06&quot;,&quot;line&quot;:&quot;4L+&quot;,&quot;start_date&quot;:&quot;2025-02-06&quot;,&quot;status&quot;:&quot;Refractory&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;23&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Refractory&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Refractory&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2025-06-06&quot;,&quot;evidence&quot;:&quot;2025-06-06 CT enhanced: retroperitoneal mass increased vs 2025-05; lesion 7.3cm, involving left renal vein/ureter, encasing aorta&quot;,&quot;type&quot;:&quot;Radiologic&quot;},&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Pathology&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2024-05-22&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Total abdominal hysterectomy with bilateral salpingo-oophorectomy + omentectomy + appendectomy + para-aortic lymph node dissection + pelvic mass resection + adhesiolysis + cytoreductive surgery&quot;},&quot;VISIT_DATE&quot;:&quot;2025-06-10&quot;,&quot;first_relapse_date&quot;:&quot;2024-08-13&quot;,&quot;last_platinum_end_date&quot;:&quot;2025-05-14&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2024-10-11&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;71.80&quot;},{&quot;date&quot;:&quot;2024-12-15&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;93&quot;},{&quot;date&quot;:&quot;2025-03-28&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;117&quot;},{&quot;date&quot;:&quot;2025-04-14&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;304&quot;},{&quot;date&quot;:&quot;2025-05-06&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;250&quot;},{&quot;date&quot;:&quot;2025-06-07&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;267&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-07&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;267&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2024-10-11&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.14&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2024-10-11&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.14&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2025-06-06&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;56&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-06&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;56&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2024-10-11&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;PROGRP 60.20 pg/mL; CYFRA21-1 2.26 ng/ml; NSE 12.80 ng/ml&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2024-10-11&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;PROGRP 60.20 pg/mL; CYFRA21-1 2.26 ng/ml; NSE 12.80 ng/ml&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2024-05-22&quot;,&quot;description&quot;:&quot;Extensive cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2024-06-27&quot;,&quot;description&quot;:&quot;Start EP chemotherapy (etoposide + cisplatin)&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2025-02-06&quot;,&quot;description&quot;:&quot;Start docetaxel + oxaliplatin + bevacizumab&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2025-06-06&quot;,&quot;description&quot;:&quot;Radiologic progression with enlarged retroperitoneal mass&quot;,&quot;type&quot;:&quot;Progression&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Recent cycle given without oxaliplatin&quot;,&quot;last_admin_date&quot;:&quot;2025-06-07&quot;,&quot;name&quot;:&quot;德曲+帕博利珠单抗&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;依托泊苷0.16g d1-3+顺铂 40mg d1-3 ivgtt，q3w（EP）&quot;,&quot;贝伐珠单抗400mg+奥沙利铂200mg d1+白蛋白结合型紫杉醇400mg d1，q3w&quot;,&quot;贝伐珠单抗400mg+奥沙利铂160mg d1+白蛋白结合型紫杉醇320mg d1，q3w&quot;,&quot;BEV+AK-104&quot;,&quot;德曲+奥铂+贝伐&quot;,&quot;德曲+帕博利珠单抗+奥沙利铂&quot;,&quot;德曲+帕博利珠单抗&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;小圆细胞恶性肿瘤&quot;],&quot;date&quot;:&quot;2024-05-22&quot;,&quot;diagnosis&quot;:&quot;符合高钙血症型小细胞癌&quot;,&quot;grade&quot;:&quot;Ki-67 80%&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;AE1/AE3&quot;,&quot;result&quot;:&quot;少+&quot;},{&quot;marker&quot;:&quot;CK&quot;,&quot;result&quot;:&quot;少+&quot;},{&quot;marker&quot;:&quot;CD20&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;CD3&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;CD99&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;SMARCA4 BRG1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;SMARCA2(BRM)&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;SMARCB1(INI-1)&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;CD10&quot;,&quot;result&quot;:&quot;少+&quot;},{&quot;marker&quot;:&quot;Desmin&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;MyoD1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Myogenin&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;少+&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;+80%&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;+&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;Syn&quot;,&quot;result&quot;:&quot;少+&quot;},{&quot;marker&quot;:&quot;CgA&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;INSM1&quot;,&quot;result&quot;:&quot;-&quot;},{&quot;marker&quot;:&quot;LCA&quot;,&quot;result&quot;:&quot;-&quot;}],&quot;involvement_sites&quot;:[&quot;Para-aortic lymph nodes 0/14 negative&quot;,&quot;Left common iliac lymph nodes 0/6 negative&quot;,&quot;Right adnexa: no special abnormality&quot;],&quot;laterality&quot;:&quot;Left&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;卵巢恶性肿瘤：（左附件及盆腔巨大肿块）小圆细胞恶性肿瘤，正在行免疫组化检查辅助诊断。补充诊断1：初步报告: （左附件及盆腔巨大肿块）小圆细胞恶性肿瘤，结合免疫组化结果，符合高钙血症型小细胞癌，大小16.5*13.5*8 cm。免疫组化结果（HI24-22759）：AE1/AE3（少+），CK（少+），CD20（-），CD3（-），CD99（+），SMARCA4 BRG1（-），SMARCA2(BRM)（-），SMARCB1(INI-1)（+），CD10（少+），Desmin（-），MyoD1（-），Myogenin（-），P53（少+），PAX8（-），Ki-67（+80%），WT1（+），ER（-），PR（-），Syn（少+），CgA（-），INSM1（-），LCA（-） ;（全子宫）内膜呈分泌改变；宫颈慢性炎。（右附件）未见特殊异常。（左卵巢血管）纤维血管组织。（阑尾）慢性炎。（腹主动脉旁）淋巴结（0/14）未见肿瘤转移。（左髂总）淋巴结（0/6）未见肿瘤转移。&quot;,&quot;sample_type&quot;:&quot;Surgical specimen&quot;,&quot;site&quot;:&quot;Left adnexa and pelvic mass; uterus; right adnexa; appendix; para-aortic and left common iliac lymph nodes&quot;,&quot;tumor_size&quot;:&quot;16.5*13.5*8 cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;No molecular/genetic testing results reported in pathology&quot;,&quot;Staging not provided&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2024-05-10&quot;,&quot;findings&quot;:[&quot;Large irregular solid pelvic mass 101*95*140mm with central multicystic area; mass abutting anterior uterine wall; heterogeneous enhancement&quot;],&quot;impression&quot;:&quot;Pelvic mass, sarcoma possible&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2024-08-13&quot;,&quot;findings&quot;:[&quot;Postoperative changes; mesenteric and peritoneal scattered nodules&quot;],&quot;impression&quot;:&quot;Consider metastatic disease&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Abdomen/retroperitoneum&quot;],&quot;date&quot;:&quot;2024-09-02&quot;,&quot;findings&quot;:[&quot;New multiple enlarged retroperitoneal lymph nodes&quot;],&quot;impression&quot;:&quot;Possible metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Abdomen/retroperitoneum&quot;],&quot;date&quot;:&quot;2024-12-09&quot;,&quot;findings&quot;:[&quot;Multiple enlarged retroperitoneal lymph nodes, some slightly smaller than before; possible involvement of left ureter upper segment with left hydronephrosis; small ascites&quot;],&quot;impression&quot;:&quot;Retroperitoneal lymphadenopathy; consider clinical correlation&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Mixed&quot;},{&quot;anatomic_sites&quot;:[&quot;Retroperitoneum, pelvis, inguinal regions&quot;],&quot;date&quot;:&quot;2025-02-01&quot;,&quot;findings&quot;:[&quot;Multiple retroperitoneal metastatic lesions, some may involve left ureter and kidney; multiple pelvic and bilateral inguinal lymph nodes&quot;],&quot;impression&quot;:&quot;Metastatic disease in retroperitoneum and pelvis&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Retroperitoneum&quot;],&quot;date&quot;:&quot;2025-05-06&quot;,&quot;findings&quot;:[&quot;Lesion measured 4.6*4.2 cm&quot;],&quot;impression&quot;:&quot;Residual/metastatic lesion&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;},{&quot;anatomic_sites&quot;:[&quot;Retroperitoneum, left kidney region&quot;],&quot;date&quot;:&quot;2025-06-06&quot;,&quot;findings&quot;:[&quot;Retroperitoneal mass larger vs 2025-05; lesion 7.3 cm, involving left renal vein and ureter, psoas muscle, encasing abdominal aorta; hepatic left lobe hemangioma&quot;],&quot;impression&quot;:&quot;Progression of retroperitoneal metastatic disease&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2024-05-10&quot;,&quot;description&quot;:&quot;Pelvic MRI showed large irregular solid mass 101*95*140mm with central multicystic change; pelvic mass, sarcoma possible&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;101*95*140mm mass, central multicystic, heterogeneous enhancement&quot;,&quot;regimen_or_test&quot;:&quot;Pelvic MRI&quot;},{&quot;date&quot;:&quot;2024-05-22&quot;,&quot;description&quot;:&quot;Extensive cytoreductive surgery including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, para-aortic lymph node dissection, pelvic mass resection&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Specimens: left adnexa and pelvic mass; nodes negative (0/14 para-aortic, 0/6 left common iliac)&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2024-05-22&quot;,&quot;description&quot;:&quot;Pathology preliminary: small round cell malignant tumor; with IHC consistent with high‑calcemia small cell carcinoma; tumor size 16.5*13.5*8 cm&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Diagnosis: 符合高钙血症型小细胞癌; Ki-67 80%; WT1+, ER-, PR-&quot;,&quot;regimen_or_test&quot;:&quot;Pathology/IHC&quot;},{&quot;date&quot;:&quot;2024-06-27&quot;,&quot;description&quot;:&quot;Started EP regimen (etoposide + cisplatin); consented to clinical trial&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;C1 start&quot;,&quot;regimen_or_test&quot;:&quot;依托泊苷0.16g d1-3+顺铂 40mg d1-3 ivgtt，q3w&quot;},{&quot;date&quot;:&quot;2024-08-13&quot;,&quot;description&quot;:&quot;Pelvic MRI after surgery/chemo: mesenteric and peritoneal nodules, consider metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Mesenteric/peritoneal nodules suggesting metastases&quot;,&quot;regimen_or_test&quot;:&quot;Pelvic MRI&quot;},{&quot;date&quot;:&quot;2024-08-29&quot;,&quot;description&quot;:&quot;Started regimen with bevacizumab + oxaliplatin + nab‑paclitaxel&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;C1 started&quot;,&quot;regimen_or_test&quot;:&quot;贝伐珠单抗400mg+奥沙利铂200mg d1+白蛋白结合型紫杉醇400mg d1，q3w&quot;},{&quot;date&quot;:&quot;2024-10-11&quot;,&quot;description&quot;:&quot;Post-chemo labs&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 7.14 U/ml; HE4 71.80 pmol/L ↑; ROMA premenopausal 15.38% ↑&quot;,&quot;regimen_or_test&quot;:&quot;CA125, HE4, ROMA and tumor markers&quot;},{&quot;date&quot;:&quot;2024-12-09&quot;,&quot;description&quot;:&quot;CT: multiple enlarged retroperitoneal lymph nodes, some slightly smaller; left ureter upper involvement possible with hydronephrosis; small ascites&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Retroperitoneal nodes; possible left ureter involvement&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2025-02-01&quot;,&quot;description&quot;:&quot;Report: multiple retroperitoneal metastatic lesions, some involving left ureter, left kidney perirenal change; multiple pelvic/inguinal nodes&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression with retroperitoneal metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT/assessment&quot;},{&quot;date&quot;:&quot;2025-02-06&quot;,&quot;description&quot;:&quot;Started docetaxel + oxaliplatin + bevacizumab (third cycle omitted oxaliplatin)&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Platinum-containing regimen restarted&quot;,&quot;regimen_or_test&quot;:&quot;德曲+奥铂+贝伐&quot;},{&quot;date&quot;:&quot;2025-04-14&quot;,&quot;description&quot;:&quot;Docetaxel + oxaliplatin + bevacizumab given; HE4 increased&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;HE4 304&quot;,&quot;regimen_or_test&quot;:&quot;德曲+奥沙利铂+贝伐&quot;},{&quot;date&quot;:&quot;2025-05-06&quot;,&quot;description&quot;:&quot;CT: lesion measured 4.6*4.2 cm; HE4 250&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Lesion 4.6*4.2 cm&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2025-05-14&quot;,&quot;description&quot;:&quot;Regimen changed to include pembrolizumab with docetaxel and oxaliplatin&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Treatment modification&quot;,&quot;regimen_or_test&quot;:&quot;德曲+帕博利珠单抗+奥沙利铂&quot;},{&quot;date&quot;:&quot;2025-06-06&quot;,&quot;description&quot;:&quot;CT enhancement: retroperitoneal mass larger vs 2025-05; lesion 7.3 cm, increased; involvement of left renal vein, ureter, psoas, encasing aorta&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Radiologic progression&quot;,&quot;regimen_or_test&quot;:&quot;CT enhanced&quot;},{&quot;date&quot;:&quot;2025-06-07&quot;,&quot;description&quot;:&quot;Most recent documented systemic therapy: docetaxel + pembrolizumab (no oxaliplatin documented on this date)&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last documented administration 2025-06-07&quot;,&quot;regimen_or_test&quot;:&quot;德曲+帕博利珠单抗&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before deciding on further systemic or local therapy, we need ECOG, symptom burden, updated labs (including calcium/renal), and clear goals-of-care documented today.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please comment on degree of left hydronephrosis/renal vein compromise and feasibility/urgency of urologic or IR decompression based on latest CT.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Can you confirm SMARCA4/SMARCA2 IHC status and provide any existing molecular data; if none, is tissue adequate for NGS?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>From your perspective, would PET/CT add information relevant to trial eligibility or focal palliation planning despite clear CT-documented progression?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Recent CT shows rapid retroperitoneal mass enlargement with ureteric and major vascular encasement; updated chest imaging and renal function are critical for staging and urgent obstruction management decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>Given clear CT-documented progression and palliative context, clarify whether PET/CT would practically change management or trial eligibility before ordering.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Pathology confirms SCCOHT with SMARCA4/2 loss, but there is still no documented FIGO/TNM stage or any molecular profile (including SMARCA4 mutation status, HRD/BRCA, MSI/TMB, PD-L1); please obtain/assign these as they are critical for accurate characterization and potential trial eligibility.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>Given clear anatomic progression and palliative intent, PET/CT is optional unless needed for trial eligibility or precise RT planning; current PET status is unknown/needs update.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Today’s priority is reassessing ECOG, symptoms, and updated labs (especially renal function/calcium) to guide obstruction management and whether to continue any systemic therapy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please explicitly grade hydronephrosis and comment on renal vein compromise on the latest CT to inform urgency of urologic/IR decompression.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>We still lack FIGO/TNM staging and any molecular profile; please clarify stage and whether existing tissue can undergo broad NGS and germline testing support.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>I agree PET/CT is optional; please note in your report that its main role would be for specific trial eligibility or RT planning if pursued.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>On latest CT, please ensure the report explicitly grades left hydronephrosis and details renal vein/aortic encasement to guide urgency of decompression and systemic therapy safety.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>From the pathology side we still lack a formal FIGO/TNM stage and any molecular profile; please confirm if archival tissue can be sent now for broad NGS plus germline testing to support trial options.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Given likely obstructive uropathy and ineffective current regimen, today we must prioritize updated renal function, ECOG, and goals-of-care before any further systemic therapy decisions.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Confirm current performance status, symptoms, serum calcium/renal function, and clarify goals of care given rapid platinum‑refractory progression.  \n- Stop ineffective current systemic regimen; discuss focus on best supportive care versus further experimental/clinical‑trial‑based options.  \n- Obtain comprehensive molecular profiling (including SMARCA4 status confirmation, germline/somatic BRCA1/2, HRD, MSI/TMB, PD‑L1) to explore targeted/novel approaches.  \n- Urgently involve urology/interventional radiology to assess left ureter/renal vein obstruction and options for decompression or palliative intervention [@RADIOLOGY|2025-06-06].  \n- Establish schedule for close imaging and HE4 monitoring, and define clear triggers for transitioning fully to comfort‑focused care.&quot;,
  &quot;oncologist&quot;: &quot;- Now multi-relapsed, radiologic progression on ≥4 prior systemic regimens; current regimen ineffective and should be reconsidered [@CASE_VIEW|2025-06-06].  \n\n- Histology is rare small cell hypercalcemic ovarian carcinoma; no germline/somatic profiling available—broad NGS and germline panel needed.  \n\n- Organ function, ECOG, pain level, and serum calcium, renal function, and marrow reserve are unknown/needs update for further systemic therapy.  \n\n- Prior exposure includes multiple cytotoxics, anti‑angiogenic agents, and immunotherapy; cumulative toxicity profile (neuropathy, cytopenias, GI) unknown/needs update.  \n\n- Given bulky retroperitoneal mass encasing vessels, need radiation/surgery consult for local control and palliative-symptom assessment.&quot;,
  &quot;radiologist&quot;: &quot;- Marked progression of left retroperitoneal mass from 4.6×4.2 cm (05-06) to 7.3 cm, indicating worsening disease. [@IMAGING_STUDIES|2025-06-06]\n\n- Current mass invades/encases left renal vein, ureter, psoas muscle, and abdominal aorta, suggesting complex surgical resectability. [@IMAGING_STUDIES|2025-06-06]\n\n- Likely left ureteral obstruction from tumor involvement; need correlation with renal function and hydronephrosis severity. [@IMAGING_STUDIES|2025-06-06]\n\n- Overall pattern: progressive metastatic retroperitoneal and pelvic disease since 2024, with nodal and soft-tissue involvement. [@IMAGING_TRENDS|2025-06-06]\n\n- Update needed: most recent dedicated imaging of chest and liver (beyond known left-lobe hemangioma) to complete staging.&quot;,
  &quot;pathologist&quot;: &quot;- Histology and IHC support diagnosis of ovarian small cell carcinoma, hypercalcemic type, high proliferative index (Ki‑67 80%). [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- SMARCA4 and SMARCA2 loss with retained INI1 is typical for SCCOHT; neuroendocrine markers largely negative. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Lymph nodes sampled (para‑aortic, left common iliac) reported negative for metastasis. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Pathologic stage is not documented; FIGO/TNM staging needs to be assigned or confirmed. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- No germline/somatic molecular data (including SMARCA4 mutation, MSI, TMB, PD‑L1) available; comprehensive molecular profiling and germline testing needed.&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT reports available for review; current metabolic disease extent is unknown/needs update.  \n\n- Prior imaging suggests progressive retroperitoneal and pelvic metastatic disease, but without PET correlation for metabolic activity or viability.  \n\n- PET could clarify whether retroperitoneal lymphadenopathy and pelvic lesions are metabolically active, refining staging vs treated/scar tissue.  \n\n- PET may detect additional distant metastases (e.g., supradiaphragmatic nodes, bone) not characterized on prior anatomic imaging, potentially upstaging.  \n\n- Need updated PET/CT report (date, target lesions, SUV, comparison to 2025-06-06 imaging) to assess progression or recurrence.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Stop current regimen given clear radiologic progression and platinum‑refractory status; prioritize goals‑of‑care and symptom‑directed strategy [@TIMELINE|2025-06-06].  \n- Urgently assess renal function, hydronephrosis severity, and performance status to guide feasibility of further systemic or local therapies [@RADIOLOGY|2025-06-06].  \n- Refer to radiation and urologic surgery for palliative options addressing retroperitoneal mass encasing aorta, ureter, renal vein [@RADIOLOGY|2025-06-06].  \n- Arrange comprehensive molecular profiling (including SMARCA4, BRCA1/2, MSI/TMB, PD‑L1) to identify targeted/clinical‑trial options; currently unknown.  \n- Initiate early palliative care involvement for pain, renal symptom management, and to revisit patient preferences and treatment intensity.&quot;,
    &quot;oncologist&quot;: &quot;- Hold further systemic therapy decisions until ECOG, symptom burden, calcium, renal function, CBC, and LFTs are updated (all currently unknown).  \n\n- Request radiology add explicit grading of hydronephrosis and renal vein involvement on latest CT to triage urgent urology/IR decompression.  \n\n- Ask pathology to assign FIGO/TNM stage and confirm tissue adequacy for broad somatic NGS and germline testing (all unknown).  \n\n- Defer PET/CT; consider only if required for a specific clinical trial or for detailed RT planning (current PET status unknown).  \n\n- After reassessment, discuss with patient goals-of-care and balance trial/experimental options versus transition toward primarily comfort-focused, symptom-directed management.&quot;,
    &quot;radiologist&quot;: &quot;- Left retroperitoneal mass has rapidly enlarged to 7.3 cm, encasing ureter, renal vein, psoas, and aorta. [@IMAGING_STUDIES|2025-06-06]\n\n- Hydronephrosis and degree of renal impairment remain unknown; need imaging-based hydronephrosis grading and updated renal function tests. [@IMAGING_STUDIES|2024-12-09]\n\n- No recent chest or liver staging beyond known hemangioma; updated thoracoabdominal imaging is required. [@IMAGING_STUDIES|2025-06-06]\n\n- PET/CT remains optional; utility mainly for trial eligibility or RT planning rather than confirming progression. [@IMAGING_TRENDS|2025-06-06]\n\n- Overall radiologic picture: progressive metastatic retroperitoneal/pelvic disease with complex local anatomy, favoring palliative, symptom-directed local interventions. [@IMAGING_TRENDS|2025-06-06]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm pathologic FIGO/TNM stage from original resection; staging currently undocumented and required for complete characterization. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Verify remaining tumor tissue adequacy and submit for broad NGS panel plus SMARCA4 mutation, MSI/TMB, HRD/BRCA, PD‑L1. [@MOLECULAR|unknown]\n\n- Coordinate germline testing (including SMARCA4 and BRCA1/2) given SCCOHT diagnosis and young age typical for this entity. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Communicate high‑grade SCCOHT with SMARCA4/2 loss and Ki‑67 80% clearly in reports to support clinical‑trial matching. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- No current evidence of molecular results in record; ensure all new profiles are uploaded and cross‑referenced in pathology addendum. [@MOLECULAR|unknown]&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT available; current metabolic disease distribution and intensity remain unknown/needs update.  \n\n- Given clear CT-documented progression and palliative context, PET/CT is optional unless required for specific trial eligibility or RT planning.  \n\n- If performed, PET/CT could better delineate metabolically active retroperitoneal vs nodal/soft-tissue disease, aiding focused palliative RT targeting.  \n\n- PET/CT may identify unsuspected distant metastases, but is unlikely to substantially alter overall staging or prognosis at this time.  \n\n- Decision to proceed with PET/CT should follow clarification of goals of care and potential trial/RT pathways; otherwise it can be deferred.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Stop current systemic regimen given clear radiologic progression and platinum-refractory status [@CASE_CORE|2025-06-06].  \n- Obtain full-body staging (CT/MRI ± PET) and updated labs including renal function, calcium, and performance status; currently unknown.  \n- Request comprehensive germline and somatic profiling including BRCA1/2, HRD, MSI, TMB, and SMARCA4-targetable alterations; currently unknown.  \n- Convene radiation, urology, and vascular surgery to evaluate local control/palliation for mass encasing aorta and ureter [@CASE_CORE|2025-06-06].  \n- Prioritize early palliative care involvement, symptom control, and discussion of goals, including clinical trial eligibility; details currently unknown.&quot;,
    &quot;oncologist&quot;: &quot;- Defer any new systemic regimen until ECOG, symptom burden, renal function, calcium, CBC, and LFTs are updated (all unknown).  \n\n- Obtain urgent chest imaging and CT addendum explicitly grading left hydronephrosis and vascular encasement to guide urology/IR intervention urgency.  \n\n- Engage urology/IR promptly to assess and, if feasible, relieve ureteric obstruction for renal preservation and symptom control (labs/imaging details unknown).  \n\n- Ask pathology to assign FIGO/TNM stage and send archival tissue for broad somatic profiling plus germline testing; current status unknown.  \n\n- Clarify patient goals-of-care and discuss realistic benefit of further trial/experimental therapy versus transition toward primarily comfort-focused, symptom-directed management.&quot;,
    &quot;radiologist&quot;: &quot;- Large progressive left retroperitoneal mass encases ureter, renal vein, psoas, and aorta, suggesting obstructive uropathy risk. [@IMAGING_STUDIES|2025-06-06]\n\n- Explicit grading of left hydronephrosis and detailed assessment of renal vein/aortic encasement on latest CT are still required. [@IMAGING_STUDIES|2024-12-09]\n\n- Multiple retroperitoneal and pelvic metastatic lesions with bilateral inguinal nodes indicate widespread abdominopelvic disease. [@IMAGING_STUDIES|2025-02-01]\n\n- Small-volume ascites is present; no thoracic or updated liver imaging is available for current staging. [@IMAGING_STUDIES|2024-12-09]\n\n- PET/CT status is unknown; given clear CT progression, further functional imaging is optional and trial/RT-planning driven. [@IMAGING_TRENDS|2025-06-06]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm SCCOHT diagnosis with SMARCA4/2 loss and Ki‑67 80% in final integrated report to support staging. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Assign and document pathologic FIGO/TNM stage for the primary ovarian tumor; currently not recorded. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Verify archival tissue adequacy (blocks/unstained slides) and coordinate broad NGS for SMARCA4 mutation, HRD/BRCA, MSI/TMB, PD‑L1. [@MOLECULAR|unknown]\n\n- Recommend germline testing (including SMARCA4, BRCA1/2) based on SCCOHT and typical hereditary associations; genetics to manage workflow. [@HISTOLOGY_AND_IHC|2024-05-22]\n\n- Issue an addendum summarizing histology, IHC profile, and any new molecular results to facilitate clinical‑trial eligibility review. [@HISTOLOGY_AND_IHC|2024-05-22]&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT performed; metabolic tumour burden, distant disease distribution, and treatment response remain unknown/needs update.  \n\n- Given unequivocal CT progression and palliative intent, PET/CT should be reserved for specific trial eligibility or precise RT planning, if pursued.  \n\n- If obtained, PET/CT could distinguish metabolically active retroperitoneal mass vs surrounding nodes/soft tissue to refine palliative RT target volumes.  \n\n- PET/CT may reveal additional thoracic/osseous metastases, but is unlikely to meaningfully change overall staging or prognosis in this setting.  \n\n- Before ordering PET/CT, clarify trial options and RT feasibility; otherwise prioritise CT-based evaluation of obstruction and systemic safety.&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>High‑calcemia small cell carcinoma (gynecologic origin), platinum‑refractory with progressive bulky retroperitoneal mass encasing aorta/left renal vein/ureter and pelvic/inguinal nodes; Ki‑67 80%, WT1+, ER/PR–; no molecular testing; left hydronephrosis, renal/ureteral involvement, needs organ‑function–sparing options.</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.6345 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 6]
    carcinoma demonstrated that adjuvant platinum-based ChT prolonged survival, but did not prospectively evaluate his- tological subtypes.38,39 High-grade EC has a similar prog- nosis to HGSC and is worse than low-grade EC. It is not clear whether there is any survival beneﬁt for adjuvant ChT in stage …
[2] score=0.6276 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…
[3] score=0.6244 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …
[4] score=0.6174 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…
[5] score=0.6112 esmo_cpg_nonepithelialovarian_2018__v00000000 [PAGE 4]
    ment, an endometrial curettage (or hysterectomy in case of radi- cal management) must be carried out to rule out concomitant uterine cancers in patients with granulosa cell tumour [IV, B]. For SCSTs, retroperitoneal evaluation is not mandatory because of the very low incidence of retroperitoneal met…</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6345386505126953,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 6,
    &quot;text&quot;: &quot;carcinoma demonstrated that adjuvant platinum-based ChT\nprolonged survival, but did not prospectively evaluate his-\ntological subtypes.38,39 High-grade EC has a similar prog-\nnosis to HGSC and is worse than low-grade EC. It is not clear\nwhether there is any survival beneﬁt for adjuvant ChT in\nstage IA or IB CCC.40,41\nRecommendation\n7.1:\nComplete\nsurgical\nresection\nincluding total abdominal hysterectomy, bilateral salpingo-\noophorectomy, omentectomy, systematic pelvic and para-\naortic lymph node dissection, peritoneal biopsies and\ncytological analysis should be the standard surgical pro-\ncedure in stage I-II high-grade EC, CCC and high-risk\nmucinous ovarian carcinoma [IV, A].\nConsensus: 97% (38) yes, 3% (1) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.2: Patients with stage I-II high-grade\nEC should be offered adjuvant platinum-based ChT [IV, A].\nConsensus: 100% (39) yes, 0% (0) no, 0% (0) abstain (39\nvoters)\nRecommendation 7.3: Adjuvant ChT may be omitted for\nadequately staged IA or IB CCC [IV, C].\nConsensus: 90% (35) yes, 5% (2) no, 5% (2) abstain (39\nvoters)\nRecommendation 7.4: Adjuvant ChT may be considered\nfor stage IC1 CCC [IV, C].&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6276225447654724,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6244290471076965,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6174013614654541,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6111960411071777,
    &quot;doc_id&quot;: &quot;esmo_cpg_nonepithelialovarian_2018__v00000000&quot;,
    &quot;page&quot;: 4,
    &quot;text&quot;: &quot;ment, an endometrial curettage (or hysterectomy in case of radi-\ncal management) must be carried out to rule out concomitant\nuterine cancers in patients with granulosa cell tumour [IV, B].\nFor SCSTs, retroperitoneal evaluation is not mandatory because\nof the very low incidence of retroperitoneal metastases in early-\nstage disease [III, A]. Recent publications on incidence of lymph\nnode metastases in SCST support the position that lymphadenec-\ntomy is not needed in these patients [29]. SLCTs frequently have\nlow-grade malignancy, although occasionally a retiform or\npoorly differentiated (sarcomatoid) form may be malignant. In\npostmenopausal women and in patients with advanced-stage dis-\nease or with bilateral ovarian involvement, abdominal hysterec-\ntomy and bilateral salpingo-oophorectomy should be carried out\nwith careful surgical staging for SCST [III, A].\nSmall cell carcinomas of the ovary hypercalcaemic type. The prog-\nnosis of SCCOHT is very poor and the risk of extra-ovarian spread\nhigh. All suspected cases should beneﬁt from a review by an expert\npathologist and be discussed in a specialised tumour board [V, A].\nEfforts should be made to treat patients in a more homogeneous&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- Adjuvant platinum-based chemotherapy improves survival in early-stage epithelial ovarian cancer overall, but randomized trials did not prospectively stratify by histologic subtype; high‑grade endometrioid carcinoma behaves similarly to high‑grade serous and worse than low‑grade endometrioid, so is often managed with adjuvant chemotherapy analogous to high‑grade serous disease [ESGO/ESMO/ESP 2024, 1].  

- When planning therapy for recurrent disease, “platinum‑sensitive” vs “platinum‑resistant” should be treated as a continuum; clinical judgment and flexibility are required when assigning category and choosing treatment, rather than strict time‑cutoffs alone [NCCN Ovary v3.2025, 2].  

- At relapse, selection between PARP inhibitor and anti‑VEGF–based strategies should consider histologic subtype, BRCA1/2 mutation status, prior exposure to PARP inhibitors and/or bevacizumab, and cumulative prior platinum exposure, as these factors influence benefit and toxicity [ESMO Epithelial Ovarian 2023, 3].  

- For first recurrence after initial platinum‑based therapy, platinum‑based combination chemotherapy is preferred (category 1 evidence), with consideration of secondary cytoreductive surgery in appropriate candidates and integration of best supportive care where indicated [NCCN Ovary v3.2025, 4].  

- In selected cases of recurrent disease, immediate platinum‑based therapy at first recurrence is supported (category 2B) as an alternative strategy, again with individualized use of best supportive care and/or surgery based on overall goals and fitness [NCCN Ovary v3.2025, 4].  

- For sex cord‑stromal tumours, routine retroperitoneal lymph node dissection is not required because retroperitoneal metastases are rare; management should instead focus on pelvic/abdominal disease and mandatory uterine evaluation (endometrial sampling or hysterectomy) to exclude concomitant uterine cancer in granulosa cell tumours [ESMO Non‑epithelial Ovarian 2018, 5].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-17T23:18:43.341344&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2025-06-10 15:38:50.183000&quot;,
      &quot;meta_info&quot;: &quot;220422198808154721&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:18:43.341803&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;655cb07a94de&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:18:43.611934&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 0,
      &quot;img_n&quot;: 0,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2025-06-11 15:38:50&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:18:43.666016&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:19:22.741471&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;High‑calcemia small cell carcinoma (gynecologic origin), platinum‑refractory with progressive bulky retroperitoneal mass encasing aorta/left renal vein/ureter and pelvic/inguinal nodes; Ki‑67 80%, WT1+, ER/PR–; no molecular testing; left hydronephrosis, renal/ureteral involvement, needs organ‑function–sparing options.&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:19:22.741477&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:19:29.392502&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:23:07.680269&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 3102
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:23:07.681073&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T23:23:32.767199&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 804
    }
  }
]</pre>
  </details>

</body>
</html>
